Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.
Auteurs : Rugo HS, Tolaney SM, Loirat D, Punie K, Bardia A, Hurvitz SA, OShaughnessy J, Cortés J, Diéras V, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo M, Itri LM, Kalinsky K
Jaar : 2022
Journal : NPJ Breast Cancer
Volume : 8
Pagina's : 98